$ICUI
ICU MEDICAL INC/DE Stock $icui

$icui Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000088398416000063 Filed on May 10, 2016

Income Statement

Concept	2016 Q1	2015 Q1
Revenue	$89.86M	$81.48M
YoY Change	10.27%	11.27%
Cost Of Revenue	$40.62M	$38.97M
YoY Change	4.24%	4.75%
Gross Profit	$49.23M	$42.51M
YoY Change	15.8%	18.01%
Gross Profit Margin	54.79%	52.17%
Selling, General & Admin	$21.98M	$20.17M
YoY Change	8.93%	-10.41%
% of Gross Profit	44.63%	47.45%
Research & Development	$3.313M	$4.308M
YoY Change	-23.1%	18.65%
% of Gross Profit	6.73%	10.13%
Depreciation & Amortization	$4.801M	$4.629M
YoY Change	3.72%	-2.85%
% of Gross Profit	9.75%	10.89%
Operating Expenses	$25.29M	$31.54M
YoY Change	-19.82%	20.62%
Operating Profit	$23.95M	$10.97M
YoY Change	118.22%	11.1%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$147.0K	$526.0K
YoY Change	-72.05%	150.48%
Pretax Income	$24.09M	$11.50M
YoY Change	109.51%	14.0%
Income Tax	$5.932M	$1.813M
% Of Pretax Income	24.62%	15.77%
Net Earnings	$18.16M	$9.686M
YoY Change	87.49%	45.5%
Net Earnings / Revenue	20.21%	11.89%
Basic Earnings Per Share	$1.13	$0.62
Diluted Earnings Per Share	$1.08	$0.60
COMMON SHARES
Basic Shares Outstanding	16.04M shares	15.69M shares
Diluted Shares Outstanding	16.87M shares	16.23M shares

Balance Sheet

Concept	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$383.7M	$354.8M
YoY Change	8.15%	16.79%
Cash & Equivalents	$347.4M	$308.5M
Short-Term Investments	$36.40M	$46.30M
Other Short-Term Assets	$15.50M	$14.00M
YoY Change	10.71%	12.0%
Inventory	$49.24M	$37.66M
Prepaid Expenses
Receivables	$55.67M	$42.60M
Other Receivables	$11.30M	$4.900M
Total Short-Term Assets	$515.4M	$454.0M
YoY Change	13.53%	13.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$74.64M	$82.29M
YoY Change	-9.3%	-8.95%
Goodwill	$6.463M	$1.478M
YoY Change	337.28%	0.0%
Intangibles	$23.48M	$6.657M
YoY Change	252.65%	-16.92%
Long-Term Investments
YoY Change
Other Assets	$15.90M	$9.900M
YoY Change	60.61%	70.69%
Total Long-Term Assets	$120.5M	$100.3M
YoY Change	20.12%	-5.08%
TOTAL ASSETS
Total Short-Term Assets	$515.4M	$454.0M
Total Long-Term Assets	$120.5M	$100.3M
Total Assets	$636.0M	$554.3M
YoY Change	14.72%	9.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.68M	$12.55M
YoY Change	1.04%	7.12%
Accrued Expenses	$21.33M	$20.35M
YoY Change	4.81%	47.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$34.01M	$32.90M
YoY Change	3.37%	29.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.900M	$1.200M
YoY Change	141.67%	-55.56%
Total Long-Term Liabilities	$2.900M	$1.200M
YoY Change	141.67%	-55.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.01M	$32.90M
Total Long-Term Liabilities	$2.900M	$1.200M
Total Liabilities	$40.00M	$36.20M
YoY Change	10.5%	12.42%
SHAREHOLDERS EQUITY
Retained Earnings	$469.8M	$418.6M
YoY Change	12.23%	7.54%
Common Stock	$151.7M	$119.9M
YoY Change	26.48%	41.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$8.933M	$795.0K
YoY Change	1023.65%	-53.4%
Treasury Stock Shares	101.0K shares	9.000K shares
Shareholders Equity	$595.9M	$518.1M
YoY Change
Total Liabilities & Shareholders Equity	$636.0M	$554.3M
YoY Change	14.72%	9.46%

Cashflow Statement

Concept	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	$18.16M	$9.686M
YoY Change	87.49%	45.5%
Depreciation, Depletion And Amortization	$4.801M	$4.629M
YoY Change	3.72%	-2.85%
Cash From Operating Activities	$17.30M	$13.25M
YoY Change	30.52%	4.22%
INVESTING ACTIVITIES
Capital Expenditures	$3.963M	$2.357M
YoY Change	68.14%	-60.1%
Acquisitions	$0.00
YoY Change
Other Investing Activities	$4.700M	$22.60M
YoY Change	-79.2%	-476.67%
Cash From Investing Activities	$560.0K	$20.02M
YoY Change	-97.2%	-266.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$16.90M	$1.435M
YoY Change	1077.49%	-75.41%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$10.28M	$7.442M
YoY Change	-238.12%	701.08%
NET CHANGE
Cash From Operating Activities	$17.30M	$13.25M
Cash From Investing Activities	$560.0K	$20.02M
Cash From Financing Activities	-$10.28M	$7.442M
Net Change In Cash	$7.576M	$40.71M
YoY Change	-81.39%	2370.15%
FREE CASH FLOW
Cash From Operating Activities	$17.30M	$13.25M
Capital Expenditures	$3.963M	$2.357M
Free Cash Flow	$13.33M	$10.89M
YoY Change	22.38%	60.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000883984
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16080600	shares
CY2016Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	ICU MEDICAL INC/DE
CY2016Q1	icui	Debt Securities Maturity Date Range High DebtSecuritiesMaturityDateRangeHigh	2039
CY2016Q1	icui	Debt Securities Maturity Date Range Low DebtSecuritiesMaturityDateRangeLow	2016
CY2015Q1	icui	Increase Decreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes	-2392000	USD
CY2016Q1	icui	Increase Decreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes	4893000	USD
CY2015Q1	icui	Legalsettlementaccrual Legalsettlementaccrual	7100000	USD
CY2015Q1	icui	Legalsettlementcharge Legalsettlementcharge	6500000	USD
CY2015Q1	icui	Legalsettlementsincludingamountsawardedinadisputeandchargesamountspaidoutinaseparatedispute. Legalsettlementsincludingamountsawardedinadisputeandchargesamountspaidoutinaseparatedispute.	7059000	USD
CY2016Q1	icui	Legalsettlementsincludingamountsawardedinadisputeandchargesamountspaidoutinaseparatedispute. Legalsettlementsincludingamountsawardedinadisputeandchargesamountspaidoutinaseparatedispute.	0	USD
CY2016Q1	icui	Paymentsfor Repurchaseof Equityincludingcommissions PaymentsforRepurchaseofEquityincludingcommissions	15400000	USD
CY2015Q1	icui	Provision For Warranty And Returns ProvisionForWarrantyAndReturns	31000	USD
CY2016Q1	icui	Provision For Warranty And Returns ProvisionForWarrantyAndReturns	39000	USD
CY2016Q1	icui	Treasury Stock Purchase Plan TreasuryStockPurchasePlan	40000000	USD
CY2016Q1	icui	Treasury Stock Purchase Plan Remaining Available TreasuryStockPurchasePlanRemainingAvailable	7200000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13670000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	12678000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	57847000	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	55674000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28948000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21328000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	148728000	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	153100000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-20758000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-16659000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	145125000	USD
CY2016Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	150090000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1101000	USD
CY2016Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1131000	USD
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	76000	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	101000	shares
CY2015Q4	us-gaap	Assets Assets	626825000	USD
CY2016Q1	us-gaap	Assets Assets	635957000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	505007000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	515434000	USD
CY2015Q4	us-gaap	Assets Held For Sale Long Lived Fair Value Disclosure AssetsHeldForSaleLongLivedFairValueDisclosure	4134000	USD
CY2016Q1	us-gaap	Assets Held For Sale Long Lived Fair Value Disclosure AssetsHeldForSaleLongLivedFairValueDisclosure	4304000	USD
CY2015Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	4134000	USD
CY2016Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	4304000	USD
CY2016Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	41233000	USD
CY2016Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	36351000	USD
CY2016Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2015Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	144000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	522000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	275812000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	308533000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	336164000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	347370000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	32721000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	11206000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	377397000	USD
CY2016Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	383721000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15595000	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16175000	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15595000	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16074000	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	1608000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	1618000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-405000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	20000000	USD
CY2015Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	0	USD
CY2016Q1	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	0	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	38970000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	40622000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	17099000	USD
CY2016Q1	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	15949000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1372000	USD
CY2016Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3170000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4629000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4801000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.62
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.99
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.60
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.96
CY2015Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-7987000	USD
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	3630000	USD
CY2015Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.16
CY2016Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.34
CY2016Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2015Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	3059000	USD
CY2016Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	2511000	USD
CY2015Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2000	USD
CY2016Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	6463000	USD
CY2016Q1	us-gaap	Goodwill Goodwill	6463000	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	42514000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	49233000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	11499000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	24092000	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1813000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8191000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1951000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1383000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4947000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2552000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3300000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8014000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1785000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4866000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	980000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3474000	USD
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	541000	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	514000	shares
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23936000	USD
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23476000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14669000	USD
CY2016Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	17737000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	43632000	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	49240000	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	24681000	USD
CY2016Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	26703000	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4282000	USD
CY2016Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	4800000	USD
CY2015Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	943000	USD
CY2016Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	528000	USD
CY2015Q1	us-gaap	Legal Fees LegalFees	700000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	626825000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	635957000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	42618000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	34006000	USD
CY2015Q4	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	1476000	USD
CY2016Q1	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	1380000	USD
CY2015Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	1488000	USD
CY2016Q1	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	1488000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7442000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7768000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	20015000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	560000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13251000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	14784000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	526000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	147000	USD
CY2016Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	31541000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	25288000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	10973000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	23945000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-10091000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4099000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-2720000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	1159000	USD
CY2015Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	161000	USD
CY2016Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	6000	USD
CY2015Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1435000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	16897000	USD
CY2016Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	1196000	USD
CY2016Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1500000	USD
CY2015Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	208000	USD
CY2016Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	219000	USD
CY2015Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9205000	USD
CY2016Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	7061000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2357000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3963000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.00
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.00
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7631000	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11198000	USD
CY2015Q4	us-gaap	Prepaid Taxes PrepaidTaxes	14366000	USD
CY2016Q1	us-gaap	Prepaid Taxes PrepaidTaxes	11297000	USD
CY2015Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	31785000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	11802000	USD
CY2015Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4777000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5421000	USD
CY2015Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1041000	USD
CY2016Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1197000	USD
CY2015Q1	us-gaap	Profit Loss ProfitLoss	9686000	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	15901000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	223048000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	227735000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	74320000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	74635000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4308000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3313000	USD
CY2016Q1	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2015Q4	us-gaap	Restructuring Reserve RestructuringReserve	6539000	USD
CY2016Q1	us-gaap	Restructuring Reserve RestructuringReserve	5560000	USD
CY2016Q1	us-gaap	Restructuring Reserve Translation Adjustment RestructuringReserveTranslationAdjustment	217000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	453896000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	469797000	USD
CY2015Q1	us-gaap	Revenues Revenues	81484000	USD
CY2016Q1	us-gaap	Revenues Revenues	89855000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	81323000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	89849000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20174000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21975000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2813000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3808000	USD
CY2016Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	17528	shares
CY2016Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	174885	shares
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	579871000	USD
CY2016Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	595913000	USD
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2016Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	101000	shares
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2016Q1	us-gaap	Treasury Stock Value TreasuryStockValue	8933000	USD
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16234000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16556000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15693000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16042000	shares
CY2016Q1	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments address several aspects of the accounting for share-based payment award transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in this update are effective for annual periods beginning after December 15, 2016. Early adoption is permitted for an entity in any interim or annual period. An entity that elects early adoption must adopt all of the amendments in the same period and any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). The amendments clarify the principal versus agent guidance in determining whether to recognize revenue on a gross or net basis. The effective dates of the amendments in this update align with those of ASU 2014-09 detailed below. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The amendments in this update requires an entity to recognize a right-of-use asset and lease liability for all leases with terms of more than 12 months. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. The amendments also require certain quantitative and qualitative disclosures about leasing arrangements. The amendments in this update will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The updated guidance requires a modified retrospective adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which amends certain aspects of recognition, measurement, presentation and disclosure of financial instruments. This amendment requires all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in the consolidation of the investee). The amendments in this update will be effective for fiscal years beginning after December 15, 2017. Early adoption of the amendments is not permitted with the exception of the provision requiring the recognition in other comprehensive income the fair value change from instrument-specific credit risk measured using the fair value option for financial instruments. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. ASU 2015-16 requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined, including the cumulative effect of the change in provisional amount as if the accounting had been completed at the acquisition date. The adjustments related to previous reporting periods since the acquisition date must be disclosed by income statement line item either on the face of the income statement or in the notes. The amendments are effective prospectively for the fiscal years, and interim reporting periods within those years, beginning on or after December 15, 2015. The adoption of this ASU did not have a material impact on our consolidated financial statements.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU No. 2015-11 Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 changes the measurement of inventory from lower of cost or market to lower of cost and net realizable value. The amendments are effective prospectively for the fiscal years, and interim reporting periods within those years, beginning on or after December 15, 2016. We do not anticipate a material impact on our consolidated financial statements from adoption of this ASU.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU No. 2014-09.  On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period. ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We adopted this ASU on a prospective basis. The adoption did not have a material impact on our consolidated financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0000883984-16-000063-index-headers.html	Edgar Link	pending
0000883984-16-000063-index.html	Edgar Link	pending
0000883984-16-000063.txt	Edgar Link	pending
0000883984-16-000063-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
icui-20160331.xml	Edgar Link	completed
icui-20160331.xsd	Edgar Link	pending
icui-20160331_cal.xml	Edgar Link	unprocessable
icui-20160331_def.xml	Edgar Link	unprocessable
icui-20160331_lab.xml	Edgar Link	unprocessable
icui-20160331_pre.xml	Edgar Link	unprocessable
icui-ex311_20160331x10q.htm	Edgar Link	pending
icui-ex312_x20160331x10q.htm	Edgar Link	pending
icui-ex321_x20160331x10q.htm	Edgar Link	pending
icui0331201610-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ICUI
ICU MEDICAL INC/DE Stock $icui

2016 Q1 Form 10-Q Financial Statement

#000088398416000063 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICUI ICU MEDICAL INC/DE Stock $icui

2016 Q1 Form 10-Q Financial Statement

#000088398416000063 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICUI
ICU MEDICAL INC/DE Stock $icui